NRSN
Neurosense Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$29.02M
P/E Ratio
—
EPS
$-0.44
Beta
1.68
52W High
$2.60
52W Low
$0.63
50-Day MA
$0.79
200-Day MA
$1.05
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Neurosense Therapeutics Ltd
Neurosense Therapeutics Ltd (NRSN) is a pioneering clinical-stage biotechnology company committed to transforming the landscape of neurodegenerative disease treatment, particularly focusing on Parkinson's disease. Leveraging its proprietary development platform, Neurosense is advancing a robust pipeline of innovative therapeutic candidates currently in pivotal clinical trials, addressing substantial unmet medical needs in neurology. With a seasoned management team and strategic collaborations, the company is poised to deliver cutting-edge therapies that significantly improve patient outcomes and strengthen its position within the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.07M |
| Operating Margin | 0.00% |
| Return on Equity | -2175.00% |
| Return on Assets | -247.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.05 |
| Price-to-Book | 2.64 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $35.35M |
| Float | $26.03M |
| % Insiders | 32.30% |
| % Institutions | 0.98% |
Historical Volatility
HV 10-Day
46.54%
HV 20-Day
64.47%
HV 30-Day
59.77%
HV 60-Day
70.07%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($8.38 target)
4
BuyData last updated: 5/1/2026